<DOC>
	<DOCNO>NCT02873338</DOCNO>
	<brief_summary>The purpose study determine whether CX-01 give together standard induction consolidation therapy acute myeloid leukemia ( AML ) increase effectiveness induction/consolidation therapy . Three different dos CX-01 study safety tolerability assess .</brief_summary>
	<brief_title>Randomized Study CX-01 Combined With Standard Induction Therapy Newly Diagnosed Acute Myeloid Leukemia</brief_title>
	<detailed_description>This randomize open-label study design evaluate whether addition either 3 different dose level CX-01 standard induction therapy consolidation therapy beneficial effect newly diagnose AML patient ( 60 year age old ) compare patient receive standard induction consolidation chemotherapy alone . 160 patient randomize one 4 treatment group receive standard induction/consolidation therapy alone standard induction/consolidation therapy CX-01 one 3 different dose level ( low , medium high ) . Patients receive 2 induction cycle 3 consolidation cycle participate study 18 month . Clinical laboratory test conduct routinely , bone marrow aspirate biopsy perform induction cycle . Safety monitor adverse event clinical laboratory result .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>Newly diagnose , de novo secondary , previously untreated AML Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Acute promyelocytic leukemia Prior chemotherapy AML Prior intensive chemotherapy stem cell transplantation treatment myelodysplastic syndrome CNS leukemia</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>